Sanchari Bhattacharyya, Ph.D.
Affiliations: | 2011 | Yeshiva University, New York, NY, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Sanchari Bhattacharyya"Parents
Sign in to add mentor| Joseph Locker | grad student | 2011 | Yeshiva University | |
| (Modeling long-distance transcriptional regulation by targeted integration.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ferri-Borgogno S, Barui S, McGee AM, et al. (2020) Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis. Cancers. 12 |
| Bhagat TD, Von Ahrens D, Dawlaty M, et al. (2019) Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 8 |
| Jeong JJ, Gu X, Nie J, et al. (2019) Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery |
| Jeong JJ, Gu X, Nie J, et al. (2019) Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. Cancer Discovery |
| Shenoy N, Bhagat TD, Cheville JC, et al. (2019) Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. The Journal of Clinical Investigation |
| Shastri A, Choudhary G, Teixeira M, et al. (2018) Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. The Journal of Clinical Investigation |
| Bhattacharyya S, Pradhan K, Campbell N, et al. (2017) Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research |
| Bachegowda L, Morrone K, Winski SL, et al. (2016) Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Research |
| Shastri A, Teixeira M, Bhattacharyya S, et al. (2016) Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3 Blood. 128: 4314-4314 |
| Cimmino L, Dawlaty MM, Ndiaye-Lobry D, et al. (2015) TET1 is a tumor suppressor of hematopoietic malignancy. Nature Immunology. 16: 653-62 |